地塞米松联合人参皂苷 Rh2 对鼻咽癌化疗效果的影响第 30 卷第 2期() 2013 年湖北民族学院学报· 医学版 Journal of Hubei University for Nationalities · Medical Edition Vol . 30 No .2P. 33 2013 地塞米松联合人参皂苷 Rh2 对鼻咽癌化疗效果的影响 111 2* 吴慧玲,董盛宇,叶耀耀,周慧 1 .吴川市人民医院五官科( 广东吴川 524500) 2 .广东医学院附属医院耳鼻咽喉科( 广东湛江 524000) 【摘要】目的探讨地塞米松和人参皂苷 Rh2 对鼻咽癌化疗效果的影响。方法将常规培养的人低分化鼻咽癌细 E - 2Z分为空白对照组,单纯紫杉醇处理组,地塞米松预处理+ 紫杉醇组,地塞米松预处理+ 人参皂苷 Rh2+ 紫杉醇组。 MTT 法检测各组细胞的 OD 值并计算被各处理因素作用后的细胞增殖率。 RT- PCR 检测细胞中与凋亡有关的基因 Cyclin D1 和 Caspase - 12 的表达。结果地塞米松对紫杉醇处理 E - 2Z 细胞中凋亡基因 Caspase - 12 的上调和原癌基因 cyclinD1 的下调均产生显著的抑制, 紫杉醇诱导的细胞凋亡现象部分被地塞米松所逆转,导 E - 2Z 细胞的存活率增高。而加入了人参皂苷 Rh2 后,地塞米松的这种逆转效应被部分抑制。结论地塞米 E - 2Z 细胞对化疗药物紫杉醇的敏感性。而人参皂苷 Rh2 能够对抗地塞米松的这种效应,部分恢复了肿瘤细胞对紫杉醇的敏感性。【关键词】鼻咽癌化疗; 紫杉醇; 糖皮质激素; 人参皂苷【中图分类号】 R739 .6【文献标识码】A【文章编号】 1008 - 8164( 2013) 02- 0033 - 04 Effects of Dexamethasone( DEX) and Ginsenoside Rh2 ( GSRh2) on Nasopharyngeal Carcinoma by Chemotherapy WU Hui - ling , DONG Sheng - yu, YE Yao - yao , et al. (1. Department of Otolaryngology , Wuchuan People's Hospital , Wuchuan 524500 , China; 2. Department of Otolaryngology , Affiliated Hospital of Guangdong Medical College , Zhanjiang 524500 , China) 【 Abstract 】 Objective To investigate the influence of mechanism of dexamethasone( DEX) and ginsenoside Rh2 ( GSRh2) on tumor cells - CNE - 2Z by Paclitaxel chemotheraping . Methods Na- sopharyngeal carcinoma E - 2Z were treated with Paclitaxel or DEX pretreatment , bined with GSRh2 . The cell proliferation was measured by the MTT - assay; Expression of Caspase - 12 and cyclin D1 were detected by RT- PCR for mechanism of DEX and GS in cellular Apoptosis signaling pathway . Results DEX reduced the effect of Paclitaxel - induced proliferation inhibition and apoptosis induction E - 2Z cells . On the other hand , bined with GS Rh2 , the tumor cells sensitivity to the Paclitaxel was partial restoration . Conclusion DEX could inhibit the effect of the growth inhibition and apoptosis induction by the chemotherapeutic drugs Paclitaxel , but GSRh2 could reverse these effe
地塞米松联合人参皂苷Rh2对鼻咽癌化疗效果的影响 来自淘豆网m.daumloan.com转载请标明出处.